ELAVL1 and pancreatic neoplasm: Considering that cytoplasmic HuR expression is higher in more aggressive CRPC than in hormone-sensitive prostate cancer (HSPC) [17] and that the inhibitor KH-3, which blocks the HuR-mRNA interaction, can significantly mitigate the progression of breast and pancreatic cancer [18, 19], we hypothesized that HuR plays a role in CRPC progression by regulating amino acid metabolism.